Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic IL-15–activated natural killer cells
- Development stage
- Unknown
- Lead developer
- Fundación de Investigación Biomédica
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic IL-15–activated natural killer cells (IL15-NK) is an investigational adoptive cellular immunotherapy consisting of donor-derived natural killer (NK) cells that have been stimulated ex vivo with interleukin-15 (IL-15). This activation process is designed to enhance the cells' proliferation, survival, and cytotoxic activity against malignant cells. The therapy is primarily being evaluated in the context of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) for high-risk pediatric patients with hematological malignancies, such as acute leukemia. By leveraging the natural graft-versus-leukemia (GvL) effect, these activated NK cells aim to eliminate residual leukemic cells and prevent relapse, particularly in cases where donor-recipient NK cell alloreactivity (KIR mismatch) is absent. The development is led by the Fundación de Investigación Biomédica del Hospital Universitario La Paz (FIBHULP) in collaboration with the Spanish Hematopoietic Stem Cell Transplantation Group (GETH).
- Other names
- IL-15-activated NK cellsIL15-activated NK cellsIL 15-activated NK cellsallogeneic IL-15-stimulated natural killer cells
02
Targets
NKG2D (Natural killer group 2 member D receptor)NCR3 (Natural cytotoxicity trigger receptor 3 (NKp30))IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)KIR/NKG2A (Killer-cell immunoglobulin-like receptor and Killer cell lectin-like receptor subfamily C member 1)
Beyond the preview
Go deeper on allogeneic IL-15–activated natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic IL-15–activated natural killer cells.